OM
SNDX icon

Opaleye Management’s Syndax Pharmaceuticals SNDX Stock Holding History

Opaleye Management’s Portfolio SNDX Stock Details SNDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-222,500
Closed -$3.17M – 41
2018
Q1 		$3.17M Buy
+222,500
New +$2.36M 0.91% 29

Other funds holding SNDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Opaleye Management's SNDX Position: Q2 2018 in Review

Opaleye Management sold out of Syndax Pharmaceuticals (SNDX) in Q2 2018, closing a stake of 222,500 shares — an estimated $3.17M sold.

Opaleye Management first reported a position in SNDX in Q1 2018 and held it in 1 quarter. The position peaked at $3.17M in Q1 2018. 84 funds tracked by Wall St. Rank hold SNDX as of Q2 2018.

  • Opaleye Management reported no remaining Syndax Pharmaceuticals position as of Q2 2018 after selling out during the quarter.
  • Opaleye Management sold 222,500 Syndax Pharmaceuticals shares in Q2 2018, an estimated $3.17M.
  • Opaleye Management first reported a position in Syndax Pharmaceuticals in Q1 2018 and held it in 1 quarter.
  • Opaleye Management's Syndax Pharmaceuticals position peaked at $3.17M in Q1 2018.
  • 84 funds tracked by Wall St. Rank held Syndax Pharmaceuticals as of Q2 2018.

Based on Opaleye Management's 13F filing for Q2 2018, filed 14 Aug 2018.